Hormone therapy discontinuation: physician practices after the Women's Health Initiative.
OBJECTIVE
No guidelines or randomized trials address best practices for hormone therapy (HT) discontinuation.


METHODS
We conducted a survey study to explore HT discontinuation practices at Group Health and Harvard Vanguard, large integrated health systems in the Northwest and Northeast United States, focusing on differences between specialties and study site.


RESULTS
The response rate to the written questionnaire (mailed between December 2005 and May 2006) was 78.5% (736/928); this article reports the results for 483 eligible physicians. To discontinue oral HT, most physicians (91%) advised tapering, not immediate cessation (8%), and most (60%) suggested decreasing both dose and days per week. Almost 60% of physicians reported no experience with tapering patches. Harvard Vanguard physicians were more likely than Group Health physicians to encourage discontinuing HT and less likely to recommend resuming HT when a woman's symptoms returned after discontinuing HT. Physicians were most strongly influenced by their own experience (48%), advice from colleagues (25%), and the woman's preference (19%) when choosing a discontinuation strategy; only 2% relied on research evidence. Physicians endorsed various approaches to manage symptoms after HT discontinuation, most often behavioral changes (44%) and increased exercise (37%), and these approaches were more often endorsed by Harvard Vanguard physicians and obstetrician/gynecologists than Group Health physicians or family practitioners or internists.


CONCLUSIONS
Two health plans in the Northwestern and Northeastern United States have no standard protocol for HT discontinuation. Physicians customized approaches, influenced by their location, colleagues, and specialty. Research is needed to guide approaches to HT discontinuation.
Newton
Katherine M
KM
Group Health Research Institute, Seattle, WA, USA. newton.k@ghc.org
Reed
Susan D
SD
Grothaus
Louis C
LC
La Croix
Andrea Z
AZ
Nekhlyudov
Larissa
L
Ehrlich
Kelly
K
Ludman
Evette J
EJ
D000368:Aged; D000369:Aged, 80 and over; D001291:Attitude of Health Personnel; D000529:Complementary Therapies; D004032:Diet; D015444:Exercise; D005194:Family Practice; D005260:Female; D006176:Gynecology; D015438:Health Behavior; D020249:Hormone Replacement Therapy / Q000706:statistics & numerical data*; D006801:Humans; D008875:Middle Aged; D009774:Obstetrics; D057240:Patient Preference; D010379:Peer Group; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires; D014481:United States
Ann Intern Med. 1999 Apr 6;130(7):545-53
10189323
Obstet Gynecol. 2003 Dec;102(6):1233-9
14662209
Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042-50
15516400
Menopause. 2018 Nov;25(11):1172-1179
30358709
Menopause. 2001 Sep-Oct;8(5):361-7
11528363
J Gen Intern Med. 2007 Sep;22(9):1311-6
17634782
Tidsskr Nor Laegeforen. 1998 Aug 20;118(19):2940-3
9748831
Ann Intern Med. 2004 Feb 3;140(3):184-8
14757616
Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1438-44
2240084
Ann Intern Med. 2006 Dec 19;145(12):869-79
17179056
Obstet Gynecol. 1998 Oct;92(4 Pt 1):580-4
9764632
Maturitas. 2001 Jul 25;39(1):1-10
11451615
Obstet Gynecol. 2003 Dec;102(6):1225-32
14662208
Am J Obstet Gynecol. 2007 Feb;196(2):97-106
17306645
J Womens Health. 1998 Sep;7(7):879-84
9785314
Obstet Gynecol. 2005 May;105(5 Pt 1):953-61
15863530
Am J Med. 2005 Dec 19;118 Suppl 12B:98-108
16414334
Am J Epidemiol. 1997 Mar 15;145(6):536-45
9063344
Menopause. 2004 Nov-Dec;11(6 Pt 1):589-600
15545786
J Womens Health. 1997 Aug;6(4):459-65
9279834
Am J Epidemiol. 1997 Nov 15;146(10):870-80
9384207
Menopause. 2002 Sep-Oct;9(5):354-9
12218724
Menopause. 2004 Jan-Feb;11(1):89-97
14716188
Obstet Gynecol. 2002 Jul;100(1):18-25
12100799
Menopause. 2007 Jan-Feb;14(1):20-8
17019376
Am J Prev Med. 1997 Sep-Oct;13(5):358-65
9315268
Maturitas. 2007 Jan 20;56(1):30-7
16797148
J Gen Intern Med. 2005 Apr;20(4):350-6
15857493